These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21777369)

  • 1. The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin.
    Fontana P; Alberts P; Sakariassen KS; Bounameaux H; Meyer JP; Santana Sorensen A
    J Thromb Haemost; 2011 Oct; 9(10):2109-11. PubMed ID: 21777369
    [No Abstract]   [Full Text] [Related]  

  • 2. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD; Müller TH
    Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the effects of anti-thromboxane agents in platelet-vessel wall interaction.
    Buccellati C; Ciceri P; Ballerio R; Casagrande C; Folco G; Nicosia S
    Eur J Pharmacol; 2002 May; 443(1-3):133-41. PubMed ID: 12044803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
    J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.
    Dogné JM; Rolin S; de Leval X; Benoit P; Neven P; Delarge J; Kolh P; Damas J; David JL; Masereel B
    Cardiovasc Drug Rev; 2001; 19(2):87-96. PubMed ID: 11484064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of terbogrel on platelet function and prostaglandin endoperoxide transfer.
    Muck S; Weber AA; Schrör K
    Eur J Pharmacol; 1998 Feb; 344(1):45-8. PubMed ID: 9570446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin.
    Hoet B; Falcon C; De Reys S; Arnout J; Deckmyn H; Vermylen J
    Blood; 1990 Feb; 75(3):646-53. PubMed ID: 2153424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade.
    Golino P; Ambrosio G; Gresele P; Pascucci I; Ragni M; Russolillo E; Leproux GB; Chiariello M
    J Pharmacol Exp Ther; 1993 Aug; 266(2):511-7. PubMed ID: 8355187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists.
    Dickinson RP; Dack KN; Long CJ; Steele J
    J Med Chem; 1997 Oct; 40(21):3442-52. PubMed ID: 9341919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet effect of a new inhibitor of thromboxane synthase and thromboxane A2 receptors.
    Tubaro E; Belogi L; Mezzadri CM
    Arzneimittelforschung; 1996 Jan; 46(1):35-41. PubMed ID: 8821515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
    Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
    J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors.
    Cimetière B; Dubuffet T; Landras C; Descombes JJ; Simonet S; Verbeuren TJ; Lavielle G
    Bioorg Med Chem Lett; 1998 Jun; 8(11):1381-6. PubMed ID: 9871770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors.
    Ackerley N; Brewster AG; Brown GR; Clarke DS; Foubister AJ; Griffin SJ; Hudson JA; Smithers MJ; Whittamore PR
    J Med Chem; 1995 May; 38(10):1608-28. PubMed ID: 7752186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
    Rollini F; Tello-Montoliu A; Patel R; Darlington A; Wilson RE; Franchi F; Muñiz-Lozano A; Desai B; Bender N; Sakariassen KS; Angiolillo DJ
    J Thromb Thrombolysis; 2014; 37(2):131-8. PubMed ID: 23943337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.